Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Berlin - Delayed Quote EUR

Merck KGaA (MRK.BE)

Compare

135.95

+1.55

+(1.15%)

At close: February 21 at 8:00:56 AM GMT+1

New CEOs to join Merck KGaA’s executive board

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Pharmaceutical Technology 3 days ago

MRK.DE
-0.70%
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

On Monday, Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks Therapeutics Inc (NASDAQ:SWTX), which has a market capitalization of $4.02 billion, according to data from Benzinga Pro. Merck Germany also confirmed that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize. Furthermore, critical conditions have yet to be met. Reuters was the first to report the potent

Benzinga 10 days ago

MRK.DE
-0.70%
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

BioPharma Dive 10 days ago

THRD

MRK.DE
-0.70%
BBIO
SpringWorks Stock Jumps More Than 30% on News of Possible Deal

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

Investopedia 11 days ago

MRK.DE
-0.70%
Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks were lower late Monday afternoon, with the NYSE Health Care Index and the Health

PREMIUM
MT Newswires 11 days ago

MRK.DE
-0.70%
Germany's Merck in advanced talks to acquire US biotech firm SpringWorks

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics. Merck, in a statement, said its negotiations to buy SpringWorks are ongoing, confirming an earlier report from Reuters. SpringWorks declined to comment.

Reuters 11 days ago

MRK.DE
-0.70%
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Fortune 16 days ago

PFE

MRK.DE
-0.70%
Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200

We recently compiled a list of the Morgan Stanley’s 15 Best European AI Stocks. In this article, we are going to take a look at where Merck KGaA (OTC:MKGAF) stands against Morgan Stanley’s other European AI stocks. In August last year, investment bank Morgan Stanley released an investor note highlighting that even though the chaos around […]

Insider Monkey 22 days ago

MRK.DE
-0.70%
MS-PQ
Merck and Opentrons to automate assay kits on custom workstation

Customers can order custom workstations and assay kits from Merck later this year.

Medical Device Network 29 days ago

MRK.DE
-0.70%
Merck KGaA's (ETR:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Merck KGaA (ETR:MRK) has had a rough three months with its share price down 14%. But if you pay close attention, you...

Simply Wall St. last month

MKGAF

MKKGY
Is Merck KGaA (MKKGY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 2 months ago

MRK.DE
-0.70%
Merck KGaA Third Quarter 2024 Earnings: Misses Expectations

Merck KGaA ( ETR:MRK ) Third Quarter 2024 Results Key Financial Results Revenue: €5.27b (up 1.8% from 3Q 2023). Net...

Simply Wall St. 3 months ago

MKGAF

MKKGY
Merck KGaA (MKGAF) Q3 2024 Earnings Call Highlights: Strong Organic Growth Amid Currency Headwinds

Merck KGaA (MKGAF) reports robust performance with 4% organic growth and confirms 2024 targets despite currency challenges.

GuruFocus.com 3 months ago

MRK.DE
-0.70%
Is Merck KGaA (MKKGY) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 3 months ago

MRK.DE
-0.70%
Merck opens new SOD facility in South Korea

This is the second SOD application center that Merck has established in Asia to meet the region’s high demand.

Investment Monitor 4 months ago

MRK.DE
-0.70%
Merck unveils $318m biosafety testing facility in Maryland, US

The launch of the facility is aimed at meeting rising global demand for biosafety testing services.

Pharmaceutical Technology 4 months ago

MRK.DE
-0.70%
MilliporeSigma invests $290m in biosafety facility in Maryland

The new facility concentrates biosafety testing, analytical development, and cell bank manufacturing services into one building.

Investment Monitor 4 months ago

MRK.DE
-0.70%
Merck KGaA's (ETR:MRK) earnings growth rate lags the 11% CAGR delivered to shareholders

When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is...

Simply Wall St. 4 months ago

MKGAF

MKKGY
Merck KGaA doses first subject in Phase III generalised Myasthenia Gravis trial

The trial is designed to enrol 240 patients diagnosed with gMG.

Clinical Trials Arena 5 months ago

MRK.DE
-0.70%
Merck KGaA (MKGAF): Morgan Stanley is Bullish on This European AI Stock Now

We recently compiled a list of the 15 Best European AI Stocks According to Morgan Stanley. In this article, we are going to take a look at where Merck KGaA (OTC:MKGAF) stands against the other European AI stocks approved by Morgan Stanley. There are several ways that investors are approaching the artificial intelligence (AI) boom that […]

Insider Monkey 6 months ago

MRK.DE
-0.70%

Performance Overview

Return	MRK.BE	DAX P
YTD	-2.44%	+11.95%
1-Year	-9.85%	+30.20%
3-Year	-18.65%	+51.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck KGaA (MRK.BE)

New CEOs to join Merck KGaA’s executive board

Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

SpringWorks Stock Jumps More Than 30% on News of Possible Deal

Sector Update: Health Care Stocks Softer Late Afternoon

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Merck KGaA (MKGAF) Faces 11% Stock Decline Despite AI-Driven Growth Outlook and Analyst Price Target of €200

Merck and Opentrons to automate assay kits on custom workstation

Merck KGaA's (ETR:MRK) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Is Merck KGaA (MKKGY) Stock Undervalued Right Now?

Merck KGaA Third Quarter 2024 Earnings: Misses Expectations

Merck KGaA (MKGAF) Q3 2024 Earnings Call Highlights: Strong Organic Growth Amid Currency Headwinds

Is Merck KGaA (MKKGY) a Great Value Stock Right Now?

Merck opens new SOD facility in South Korea

Merck unveils $318m biosafety testing facility in Maryland, US

MilliporeSigma invests $290m in biosafety facility in Maryland

Merck KGaA's (ETR:MRK) earnings growth rate lags the 11% CAGR delivered to shareholders

Merck KGaA doses first subject in Phase III generalised Myasthenia Gravis trial

Merck KGaA (MKGAF): Morgan Stanley is Bullish on This European AI Stock Now

Performance Overview